Apollo Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Apollo Therapeutics's estimated annual revenue is currently $9.6M per year.
- Apollo Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Apollo Therapeutics has 62 Employees.
- Apollo Therapeutics grew their employee count by 55% last year.
Apollo Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Chief Regulatory, Quality & Compliance Officer | Reveal Email/Phone |
3 | Chief Business Officer | Reveal Email/Phone |
4 | VP & Head Immunology & Inflammation Clinical Development | Reveal Email/Phone |
5 | Head Finance | Reveal Email/Phone |
6 | Head Medicinal Chemistry | Reveal Email/Phone |
7 | Chief Financial Officer | Reveal Email/Phone |
8 | Program Director | Reveal Email/Phone |
9 | Program Director | Reveal Email/Phone |
10 | Program Director | Reveal Email/Phone |
Apollo Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Apollo Therapeutics?
N/A
Total Funding
62
Number of Employees
$9.6M
Revenue (est)
55%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Apollo Therapeutics News
2022-04-13 - Von Willebrand Disease (VWD) Therapeutics Market Analysis ...
Von Willebrand Disease (VWD) Therapeutics Market Analysis, Research Study With Apollo Therapeutics, Apotex, Bayer.
2022-04-06 - Full throttle': venture capital in 2021
Now is the time to really accelerate it and go full throttle, said Richard Butt, the Chief Scientific Officer at Apollo Therapeutics,...
2022-03-30 - APOLLO: SLN360 Clears First Major Hurdle, Hammering Lp(a)
... but with elevated Lp(a) in the small dose-ranging APOLLO trial. Following a single subcutaneous dose of SLN360 (Silence Therapeutics),...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $5.6M | 62 | 13% | N/A |
#2 | $3.5M | 62 | 3% | N/A |
#3 | $15M | 62 | 5% | N/A |
#4 | $8.1M | 62 | 5% | N/A |
#5 | $9.8M | 62 | -9% | N/A |